Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Monotherapy in Intermediate-to-High-Risk MDS
NCT07616336Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in myelodysplastic syndrome (MDS), sponsored by Zhongshan Hospital (Xiamen), Fudan University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07616336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616336.